Medicare's $50 GLP-1 bridge may never end

Starting July 1, 2026, Medicare beneficiaries aged 65 and older will be able to fill prescriptions for GLP-1 weight-loss drugs at a $50 monthly copay through a temporary demonstration called the Medicare GLP-1 Bridge^[1]. The program uses Section 402 demonstration authority to bypass a longstanding statutory ban on Medicare coverage of weight-loss medications. It was supposed to end in December 2026. It has already been extended through the end of 2027, and the political logic of taking away a benefit from millions of older Americans suggests it will not stop there.

How the Bridge works

Drug manufacturers agreed to a negotiated net price of $245 per 30-day supply. Beneficiaries pay a flat $50 monthly copay. The covered drugs are Mounjaro, Ozempic, Rybelsus, Wegovy, Zepbound (KwikPen formulation only), and Foundayo. To qualify, a provider must attest that the patient has a BMI of 30 or above, or 27 or above with weight-related comorbidities, and is prescribed the drug for weight reduction^[1].

One detail matters for cost planning: the $50 copay does not count toward the Part D deductible or the $2,400 annual out-of-pocket maximum in 2027. Low-income subsidy cost-sharing does not apply either. The Bridge sits outside the normal Part D benefit structure entirely, which means beneficiaries cannot use it to lower their other drug costs for the year.

Why it exists outside normal Medicare

Medicare Part D has explicitly excluded coverage of drugs prescribed for weight loss since the benefit was created in 2003. Congress has considered bills to change that (the Treat and Reduce Obesity Act has been reintroduced multiple sessions), but none have passed. The Trump administration chose to use demonstration authority instead, sidestepping Congress. A 2024 Health Affairs analysis estimated that full Medicare coverage of anti-obesity medications would cost $3.1 billion to $6.1 billion per year, depending on uptake rates^[2].

Why the temporary label may not hold

The Bridge was originally set to expire in December 2026, serving as a runway for a larger program called BALANCE. The BALANCE model, designed under CMS Innovation Center authority, was supposed to fold GLP-1 obesity coverage into Part D starting January 2027. That launch has been delayed indefinitely because major Part D plan sponsors declined to participate as designed^[1].

With BALANCE stalled, CMS extended the Bridge through December 2027. The political calculus is straightforward: once several million Medicare beneficiaries are filling GLP-1 prescriptions at $50 a month, the cost of ending the program is measured in angry constituents, not just dollars. Demonstration programs in Medicare have a long history of becoming permanent fixtures through repeated extensions, and this one carries more visible public demand than most.

The scale of potential enrollment is large. Medicare covers roughly 67 million Americans, and obesity prevalence among adults over 65 exceeds 40% according to CDC data. Even conservative uptake estimates suggest millions of eligible beneficiaries. The Health Affairs analysis projected that if just 5% of newly eligible patients filled prescriptions, annual Part D costs would rise by $3.1 billion; at 10% uptake, the figure would hit $6.1 billion^[2]. Those estimates predate the Bridge's negotiated $245 net price, but the order of magnitude is instructive.

What this does not resolve

The Bridge does not change the underlying statute. Congress still has not passed legislation making anti-obesity drugs a standard Part D benefit. If the demonstration authority is challenged or a future administration chooses not to renew, coverage could end abruptly. The Bridge also does not cover tirzepatide or semaglutide prescribed for their already-covered indications (type 2 diabetes, cardiovascular risk reduction) any differently; those prescriptions continue through normal Part D.

For beneficiaries, the gap between a $50 demonstration copay and full list price (often exceeding $1,000 per month) is large enough that any disruption would force difficult decisions. The KFF analysis notes that no clear pathway exists for Medicare GLP-1 obesity coverage after 2027 unless the Bridge is extended again or BALANCE finally launches^[1]. Stopping treatment abruptly also raises clinical questions: weight regain after GLP-1 discontinuation is well documented in trial data, and an abrupt coverage cutoff could leave patients mid-treatment with no affordable alternative.

Where this fits on the site

This article covers US Medicare policy. For drug-level detail, see our pages on semaglutide and tirzepatide. Country-specific regulatory and access information for other jurisdictions is on our regulation pages. If you are a Medicare beneficiary considering a GLP-1 for weight management, consult your prescriber about eligibility before July 1.